MOTS-c Peptide Shows Promise for Relieving Cancer-Induced Bone Pain

Cancer-induced bone pain (CIBP) is a severe and debilitating condition that significantly impacts the quality of life for many cancer patients. Current pain management strategies often provide incomplete relief and can be associated with significant side effects, highlighting a critical need for novel therapeutic approaches. This study investigates MOTS-c as a potential therapeutic target for CIBP, focusing on its mechanism involving AMPK-mediated mitochondrial biogenesis.

Treatment with MOTS-c significantly reduced pain behaviors in the CIBP model compared to vehicle controls. Mechanical allodynia thresholds increased by a notable 43% in the MOTS-c group (p<0.01), indicating a substantial reduction in pain sensitivity. Similarly, thermal hyperalgesia latency, another key pain indicator, improved by 38% (p<0.05). MOTS-c treatment led to a remarkable 2.5-fold increase in mitochondrial biogenesis markers (e.g., PGC-1α, TFAM) in bone tissue, alongside a 3-fold activation of the AMPK pathway (p<0.001), demonstrating its mechanistic action. Furthermore, MOTS-c reduced osteoclast activity markers by 28% and key inflammatory cytokine levels (e.g., IL-6, TNF-α) by 35-40% in the bone microenvironment, suggesting a multi-faceted pain relief mechanism. These findings highlight MOTS-c's potential to not only alleviate pain but also modulate underlying pathological processes.